BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yang S, Yang S, Zhang H, Hua H, Kong Q, Wang J, Jiang Y. Targeting Na+ /K+ -ATPase by berbamine and ouabain synergizes with sorafenib to inhibit hepatocellular carcinoma. Br J Pharmacol 2021. [PMID: 34233013 DOI: 10.1111/bph.15616] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Jiang Y, Zhang H, Wang J, Liu Y, Luo T, Hua H. Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy. J Hematol Oncol 2022;15:34. [PMID: 35331296 DOI: 10.1186/s13045-022-01252-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
2 Farooqi AA, Wen R, Attar R, Taverna S, Butt G, Xu B. Regulation of Cell-Signaling Pathways by Berbamine in Different Cancers. Int J Mol Sci 2022;23:2758. [PMID: 35269900 DOI: 10.3390/ijms23052758] [Reference Citation Analysis]
3 Hua H, Zhang H, Chen J, Wang J, Liu J, Jiang Y. Targeting Akt in cancer for precision therapy. J Hematol Oncol 2021;14:128. [PMID: 34419139 DOI: 10.1186/s13045-021-01137-8] [Cited by in F6Publishing: 17] [Reference Citation Analysis]